01
Dec
2008
Posted in I - Series A, Q - 3Q08, R - NORTH EAST, X - Diabetes, X - Endocrinology, X - Oncology, X - RNAi
Dicerna Pharmaceuticals (Watertown, MA) clinical-stage biopharmaceutical company developing RNAi therapeutics for multiple clinical applications, closed a $8.4M Series A. Participants include Abingworth, Oxford Bioscience Partners and Skyline Ventures.